Walding A[au] - Search Results

Year	Number of Results
2004	1
2005	1
2006	2
2007	1
2008	1
2009	1
2010	4
2011	3
2013	1
2017	1
2018	1
2019	2
2020	2
2021	4
2022	4

1

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K. Ohe Y, et al. Among authors: walding a. Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179. Jpn J Clin Oncol. 2019. PMID: 30508196 Free PMC article. Clinical Trial.

2

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.

Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, Liu C, Walding A, Saggese M, Huang X, Fan M, Wang J, Ramalingam SS. Cheng Y, et al. Among authors: walding a. Target Oncol. 2021 Mar;16(2):165-176. doi: 10.1007/s11523-021-00794-6. Epub 2021 Feb 5. Target Oncol. 2021. PMID: 33544337 Free PMC article. Clinical Trial.

3

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.

Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. Tsuboi M, et al. Among authors: walding a. Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19. Future Oncol. 2021. PMID: 34278827 Free PMC article. Clinical Trial.

4

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.

Leighl NB, Karaseva N, Nakagawa K, Cho BC, Gray JE, Hovey T, Walding A, Rydén A, Novello S. Leighl NB, et al. Among authors: walding a. Eur J Cancer. 2020 Jan;125:49-57. doi: 10.1016/j.ejca.2019.11.006. Epub 2019 Dec 12. Eur J Cancer. 2020. PMID: 31838405 Free article.

5

Cardiac Safety of Osimertinib: A Review of Data.

Ewer MS, Tekumalla SH, Walding A, Atuah KN. Ewer MS, et al. Among authors: walding a. J Clin Oncol. 2021 Feb 1;39(4):328-337. doi: 10.1200/JCO.20.01171. Epub 2020 Dec 23. J Clin Oncol. 2021. PMID: 33356419 Free PMC article. Review.

6

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.

Ahn MJ, Cho BC, Ou X, Walding A, Dymond AW, Ren S, Cantarini M, Jänne PA. Ahn MJ, et al. Among authors: walding a. J Thorac Oncol. 2022 May;17(5):718-723. doi: 10.1016/j.jtho.2022.01.012. Epub 2022 Feb 15. J Thorac Oncol. 2022. PMID: 35181499 Clinical Trial.

7

Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1beta-driven model of joint pathology.

Scott I, Midha A, Rashid U, Ball S, Walding A, Kerry P, Delaney S, Cruwys S. Scott I, et al. Among authors: walding a. Osteoarthritis Cartilage. 2009 Jun;17(6):790-7. doi: 10.1016/j.joca.2008.09.016. Epub 2008 Oct 17. Osteoarthritis Cartilage. 2009. PMID: 19010066 Free article.

8

Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.

Sebastian M, Rydén A, Walding A, Papadimitrakopoulou V. Sebastian M, et al. Among authors: walding a. Lung Cancer. 2018 Aug;122:100-106. doi: 10.1016/j.lungcan.2018.05.003. Epub 2018 May 7. Lung Cancer. 2018. PMID: 30032816 Free article. Clinical Trial.

9

Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists.

Luckhurst CA, Stein LA, Furber M, Webb N, Ratcliffe MJ, Allenby G, Botterell S, Tomlinson W, Martin B, Walding A. Luckhurst CA, et al. Among authors: walding a. Bioorg Med Chem Lett. 2011 Jan 1;21(1):492-6. doi: 10.1016/j.bmcl.2010.10.117. Epub 2010 Oct 27. Bioorg Med Chem Lett. 2011. PMID: 21094606

10

Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy.

Rydén A, Blackhall F, Kim HR, Pillai RN, Braam L, Martin ML, Walding A. Rydén A, et al. Among authors: walding a. Patient. 2017 Oct;10(5):593-603. doi: 10.1007/s40271-017-0229-9. Patient. 2017. PMID: 28353220 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results